P14-10. Comparable immunogenicity of VRC DNA and rAd5 HIV-1 vaccines delivered by intramuscular, subcutaneous and intradermal routes in healthy adults (VRC 011)
Retrovirology ,
Oct 2009
JE Ledgerwood , L Novik , ME Enama , IJ Gordon , LA Holman , MC Nason , RT Bailer , M Roederer , RA Koup , JR Mascola , et al.
A PDF file should load here. If you do not see its contents
the file may be temporarily unavailable at the journal website
or you do not have a PDF plug-in installed and enabled in your browser.
Alternatively, you can download the file locally and open with any standalone PDF reader:
http://www.retrovirology.com/content/pdf/1742-4690-6-S3-P198.pdf
P14-10. Comparable immunogenicity of VRC DNA and rAd5 HIV-1 vaccines delivered by intramuscular, subcutaneous and intradermal routes in healthy adults (VRC 011)
JE Ledgerwood
0
L Novik
0
ME Enama
0
IJ Gordon
0
LA Holman
0
MC Nason
0
RT Bailer
0
M Roederer
0
RA Koup
0
JR Mascola
0
GJ Nabel
0
BS Graham
0
0
Address: Clinical Trials Core, Vaccine Research Center, NIAID, NIH
,
Bethesda, MD
,
USA
-
Background
DNA and rAd5 vaccines delivered intramuscularly have
been studied in many phase I/II trials. Here, the
immunogenicity of the NIAID Vaccine Research Center (VRC)
DNA and rAd5 HIV-1 vaccines were evaluated after
injection by intramuscular (IM), subcutaneous (SC) and
intradermal (ID) routes of administration.
Methods
60 subjects were randomized to one of two schedules.
Group 1 received 3 DNA vaccine injections followed by a
recombinant adenoviral vector (rAd5) vaccine booster;
Group 2 received rAd5 prime followed by rAd5 booster.
Within each Group subjects were equally randomized to
prime injections by the IM, SC or ID routes of
administration and all groups received a boost with rAd5 by IM
injection. Half of the subjects in each group had pre-existing
Ad5 neutralizing antibody.
Results
All routes induced T cell and humoral immune responses
in Ad5 nave and pre-immune subjects. >95% of subjects
made an antibody response to Env. T cell responses to Env
were seen in >80% and T cell responses to Gag were seen
in >50% of all study subjects. Env T cell responses were of
greater magnitude than responses to Gag. The frequency
and magnitude of T cell responses were not diminished in
Ad5 pre-immune subjects as compared to nave subjects
in either of the ID primed groups.
Conclusion
In this exploratory study, SC delivery of DNA or rAd5 as a
prime does not induce a higher frequency or magnitude of
T cell immunity than IM delivery. ID delivery may provide
a dose sparing effect and also deserves additional
evaluation as a means to overcome pre-existing vector
immunity.
(...truncated)
This is a preview of a remote PDF: http://www.retrovirology.com/content/pdf/1742-4690-6-S3-P198.pdf
JE Ledgerwood, L Novik, ME Enama, IJ Gordon, LA Holman, MC Nason, RT Bailer, M Roederer, RA Koup, JR Mascola, GJ Nabel, BS Graham.
P14-10. Comparable immunogenicity of VRC DNA and rAd5 HIV-1 vaccines delivered by intramuscular, subcutaneous and intradermal routes in healthy adults (VRC 011) ,
Retrovirology,
2009, pp. P198, 6,